Prospective study of Grazoprevir and Elbasvir for HCV genotype 1 intected Japanese patients

Prospective study of Grazoprevir and Elbasvir for HCV genotype 1 intected Japanese patients - IFN free GE study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025191

Enrollment

100

Registered

2017-01-15

Start date

2016-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCV genotype 1 infected chronic liver disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HCV genotype 1 infected patients with chronic liver disease Patients satisfied the public indication for Grazoprevir and Elbasvir

Exclusion criteria

Exclusion criteria: Pregnant woman Decompensated cirrhosis hepatocellular carcinoma Doctors judge as inappropriate

Design outcomes

Primary

Measure	Time frame
Sustained viral response (12 weeks post-treatment)	—

Secondary

Measure	Time frame
Regression rate of liver fibrosis Suppressive effect on HCC incidence	—

Countries

Japan

Contacts

Public ContactRitsuzo Kozuka

Osaka City University Graduated School of medicine Department of Hepatology

m1159834@med.osaka-cu.ac.jp06-6645-3905

Outcome results